The Seattle Vaccine Trials Unit, part of Fred Hutch, is looking for volunteers to take part in a research studies for people who are at risk for COVID or have tested positive for COVID-19. Individuals are needed to help us learn more about how the virus affects the immune system.
Respiratory viruses can infect adults and cause mild to severe disease. In late 2019 a new respiratory virus named SARS-CoV-2 was found and the resulting disease is called COVID-19. Person-to-person spread of the virus has been found around the world, including Washington State. The purpose of this study is to examine different ways the body responds to COVID-19 infection. We have a number of new and innovated research studies so that we may learn how to help treat or prevent COVID-19 or other infectious diseases.
Volunteering for a study may aid in the development of a vaccine or treatment for COVID-19 or some other disease.
Potential volunteers will speak with a clinician to review study details and receive a consent form. This one-on-one time is where someone can ask questions and determine if the study is a good fit for them.
Volunteers may be asked to provide blood samples during study visits for basic medical testing, tests for the current viruses and to determine exposure to other viruses or to learn more about viruses, vaccines and the immune system. Copies of medical test results will be provided to volunteers and we encourage sharing with a primary care provider.
Volunteers may be asked to provide nasal swabs during study visits, depending on the needs of scientists in the lab.
Volunteers will be asked to come to one of the study sites for follow-up visits. We would only ask you to come in if you are well and do not have symptoms.
Dr. McElrath is one of the world’s leading HIV vaccine researchers and is director of Fred Hutch’s Vaccine and Infectious Disease Division. She is working to identify antibodies that bind to the coronavirus, research that could lead to a vaccine.
Julie Czartoski is the COVID studies initial contact for all study participants. She manages the Seattle Vaccine Trials Unit Cohort Studies which follows the long-term non-progressor and elite controller study, mucosal study, and the lab control study.